Latest News & Updates

FDA expands early breast cancer indication for abemaciclib with endocrine therapy
March 6, 2023

Continue Reading »

FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer
February 6, 2023

Continue Reading »

FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma
December 23, 2022

Continue Reading »

FDA expands early breast cancer indication for abemaciclib with endocrine therapy
March 6, 2023

Continue Reading »

FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer
February 6, 2023

Continue Reading »

FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma
December 23, 2022

Continue Reading »

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer
December 19, 2022

Continue Reading »

Get More from FLASCO With Your Partnership

The Corporate Partnership Program allows FLASCO to expand our offerings to our partneres. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Partners

Diamond Elite

Diamond

Platinum

Gold

Upcoming Events

Click to view full events calendar.

June 8, 2023 5:30 pm
Living with GIST
September 23, 2023 7:30 am
Veterans Living With Cancer
September 23, 2023 7:30 am
Veterans Living With Cancer

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: